下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEKNK437Cat.No.:HY-100110CASNo.:218924-25-5Synonyms:HeatShockProteinInhibitorI分?式:C??H??NO?分?量:245.23作?靶點(diǎn):HSP作?通路:CellCycle/DNADamage;MetabolicEnzyme/Protease儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:31.25mg/mL(127.43mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM4.0778mL20.3890mL40.7780mL5mM0.8156mL4.0778mL8.1556mL10mM0.4078mL2.0389mL4.0778mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;?旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限:-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?,-20°C儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:(為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑:10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:1.67mg/mL(6.81mM);Suspendedsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性KNK437HSP抑制劑,能夠抑制HSP105,HSP70和HSP40的活化。IC50&TargetHSP105HSP70HSP40體外研究KNK437inhibitstheactivationofseveralHSPsincludingHSP105,HSP70,andHSP40inCOLO320DM(humancoloncarcinoma)cells.KNK437(100μM)inhibitsthermotoleranceinCOLO320DMcellsafterthefirstheattreatment.KNK437showsinhibitoryeffectsonthermotolerancedose-dependentlyinCOLO320DMcells(0-200μM)andHeLaS3cells(100,200μM)[1].KNK437(100μM)exhibitsinhibitoryactivitiesagainstthemethylationofH3-Lys4beforeorafterheat-treatmentinHSC4cellsandKBcells,butdoesnotaffectthatofH3Lys9.KNK437alsosuppressestheexpressionofHSP70[3].體內(nèi)研究KNK437isaweaklytoxicagent.KNK437(62.5-400mg/kg)recoversbodyweightlossesoftumor-freeCD-1(ICR)mice.KNK437(200mg/kg)aloneshowsnoantitumoreffectsanddoesnotincreasethethermosensitivityofnontoleranttumors.KNK437improvestheantitumoreffectsoffractionatedheattreatmentat44°Cat200mg/kginasynergisticmanner.KNK437(200mg/kg,i.p.)suppressestheinductionofthermotolerancewhenadministrated6hbeforetheinitialheating[2].PROTOCOLCellAssay[1]Heattreatmentsat42°Cfor90minareperformedinaCO2incubatorusing25-cm2plasticflasks.Cells(1×105)areseededintheflasks,incubatedat37°Cfor48h,andthenheatedbyimmersingtheflasksinawaterbath(45°C±0.05°C).KNK437andquercetinaredissolvedinDMSObeforebeingaddedattheindicatedconcentrations.ThefinalconcentrationofDMSOineachculturemediumis0.25%(v/v),irrespectiveoftheconcentrationsofthedrugs.ThesameconcentrationofDMSOisusedasacontrol.SodiumarseniteisdissolvedinPBSataconcentrationof80mMandaddedtothemedium.Cellsaretreatedwith300μMsodiumarseniteat37°Cfor1.5h,rinsed,andthenincubatedat37°Cfor5hbefore45°Cheatchallenge[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalTosubjectthetumorstohyperthermia,therightfootofeachmouseisimmersedinawaterbathmaintainedAdministration[2]atthedesiredtemperaturetoanaccuracyof±0.05°C.Afterthemousehasbeenanesthetizedwith50mg/kgpentobarbitalsodiumsolution,thetumor-bearinglegispulleddownintothewaterbathusingaspecialsinker(weighing-45g)tapedtotheskinofthetoe.Careistakennottoimpairthebloodflowinthelimb.Whiletheextendedrightlegisreceivinglocalheat,themouseisair-cooled.KNK437isdissolvedinoliveoilimmediatelybeforeuse.TheKNK437isadministeredi.p.6hbeforethefirstheattreatment.Itisusedmainlyataconcentrationof200mg/kg[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE?FishShellfishImmunol.2017Nov;70:185-194.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].YokotaS,etal.Benzylidenelactamcompound,KNK437,anovelinhibitorofacquisitionofthermotoleranceandheatshockproteininductioninhumancoloncarcinomacells.CancerRes.2000Jun1;60(11):2942-8.[2].KoishiM,etal.TheeffectsofKNK437,anovelinhibitorofheatshockproteinsynthesis,ontheacquisitionofthermotoleranceinamurinetransplantabletumorinvivo.ClinCancerRes.2001Jan;7(1):215-9.[3].MatsudaK,etal.EffectsofKNK437onheat-inducedmethylationofhistoneH3inhumanoralsquamouscellcarcinomacells.IntJHyperthermia.2
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 就職表態(tài)性發(fā)言稿(7篇)
- 常用治愈晚安寄語(155句)
- 安全管理工作總結(jié)(合集)
- 合成材料制造的工藝流程控制考核試卷
- 企業(yè)培訓(xùn)中的團(tuán)隊(duì)數(shù)字時(shí)代的創(chuàng)新思維培訓(xùn)考核試卷
- 青少年夏令營(yíng)策劃方案
- 安全輔助與智能化結(jié)合考核試卷
- 客戶投訴處理妥善處理客戶投訴維持良好關(guān)系考核試卷
- 盧森堡機(jī)器人服務(wù)市場(chǎng)機(jī)會(huì)分析考核試卷
- 印刷品風(fēng)格設(shè)計(jì)與文化表達(dá)考核試卷
- 《反不正當(dāng)競(jìng)爭(zhēng)法》課件
- 《陀螺》第一課時(shí)
- 中醫(yī)冠心病護(hù)理查房
- 拳擊館計(jì)劃書
- 應(yīng)用微生物發(fā)酵改善果汁品質(zhì)
- 鍋爐安全:風(fēng)險(xiǎn)點(diǎn)防范、應(yīng)急措施與安全須知
- 醫(yī)院藥品儲(chǔ)備情況評(píng)估報(bào)告
- 以實(shí)踐為基礎(chǔ)的社會(huì)科學(xué)研究方法-實(shí)踐論
- (中職組)數(shù)字產(chǎn)品檢測(cè)與維護(hù)賽項(xiàng)選拔賽考試題庫(kù)(含答案)
- 220kV輸電線路工程質(zhì)量評(píng)估報(bào)告(標(biāo)準(zhǔn)項(xiàng)目監(jiān)理部版)
- 壓力容器考試題庫(kù)及答案題全
評(píng)論
0/150
提交評(píng)論